JGC
LKFT

J. Goldman & Co’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

J. Goldman & Co’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-84,307
Closed -$2.12M – 530
2025
Q1 		$2.12M Buy
+84,307
New +$2.13M 0.05% 286
2022
Q1 		– Sell
-27,972
Closed -$1.54M – 394
2021
Q4 		$1.54M Buy
+27,972
New +$1.46M 0.09% 230
2016
Q4 		– Sell
-50,000
Closed -$3.23M – 326
2016
Q3 		$3.23M Buy
+50,000
New +$2.82M 0.18% 153

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

J. Goldman & Co's LKFT Position: Q2 2025 in Review

J. Goldman & Co sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2025, closing a stake of 84,307 shares — an estimated $2.12M sold.

J. Goldman & Co first reported a position in LKFT in Q3 2016 and held it in 3 quarters. The position peaked at $3.23M in Q3 2016. 85 funds tracked by Wall St. Rank hold LKFT as of Q2 2025.

  • J. Goldman & Co reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2025 after selling out during the quarter.
  • J. Goldman & Co sold 84,307 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2025, an estimated $2.12M.
  • J. Goldman & Co first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2016 and held it in 3 quarters.
  • J. Goldman & Co's Lakefront Biotherapeutics American Depositary Shares position peaked at $3.23M in Q3 2016.
  • 85 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2025.

Based on J. Goldman & Co's 13F filing for Q2 2025, filed 14 Aug 2025.